Litigation Details for Exeltis USA, Inc. v. Lupin Ltd. (D. Del. 2022)

Exeltis USA, Inc. v. Lupin Ltd. (D. Del. 2022)

Docket		Date Filed	2022-04-01
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand		Referred To	Mary Pat Thynge
Patents	10,179,140; 9,603,860
Link to Docket	External link to docket

Details for Exeltis USA, Inc. v. Lupin Ltd. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-04-01	107	Opinion - Memorandum Opinion	U.S. Patent No. 9,603,860 (the “’860 patent”), U.S. Patent No. 10,179,140 (the “’140 patent”), U.…construction for multiple terms in U.S. Patent Nos. 9,603,860, 10,179,140, 10,987,364, 11,123,299, 11,291,632…U.S. Patent No. 10,987,364 (the “’364 patent”), U.S. Patent No. 11,123,299 (the “’299 patent”), U.…U.S. Patent No. 11,291,632 (the “’632 patent”), U.S. Patent No. 11,291,633 (the “’633 patent”), U.…U.S. Patent No. 11,351,122 (the “’122 patent”), U.S. Patent No. 11,413,249 (the “’249 patent”), U.	External link to document

Exeltis USA v. Lupin Litigation Summary: Slynd Patent Dispute in Delaware

Last updated: September 1, 2026

Exeltis USA, Inc. v. Lupin Ltd., No. 1:22-cv-00434-RGA-MPT, was a Hatch-Waxman patent action filed in the U.S. District Court for the District of Delaware. Exeltis sued Lupin after receiving notice that Lupin had submitted an Abbreviated New Drug Application seeking approval for a generic version of Slynd, Exeltis’ drospirenone-only oral contraceptive. The dispute centered on Exeltis’ patent covering pharmaceutical compositions containing drospirenone and the regulatory consequences of Lupin’s Paragraph IV certification.[1]

The case was assigned to District Judge Richard G. Andrews and Magistrate Judge Mary Pat Thynge. The litigation was resolved before a public merits decision establishing whether Lupin’s proposed product infringed or whether the asserted patent was valid.

What drug and patent were involved in Exeltis v. Lupin?

The case involved Slynd, a 4-mg drospirenone oral contraceptive marketed by Exeltis in the United States under NDA No. 209498. Slynd is a progestin-only oral contraceptive. Unlike combined oral contraceptives, it does not contain an estrogen component.

The asserted patent was U.S. Patent No. 10,292,918, directed to pharmaceutical compositions comprising drospirenone. The patent was listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, for Slynd.[2]

Key case data

Item	Details
Plaintiff	Exeltis USA, Inc.
Defendants	Lupin Ltd. and related Lupin entities
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:22-cv-00434-RGA-MPT
Filed	2022
Product	Slynd, drospirenone 4-mg tablets
NDA	209498
Asserted patent	U.S. Patent No. 10,292,918
Cause of action	Hatch-Waxman patent infringement
Regulatory trigger	Lupin ANDA and Paragraph IV certification
Outcome	Resolved without a public merits judgment

The asserted patent’s expected expiration was in 2033, subject to any applicable patent-term adjustment or other statutory calculation. The Orange Book listing, rather than the filing date alone, determined the patent’s role in the ANDA litigation.

What triggered the Paragraph IV lawsuit?

Lupin’s ANDA apparently included a Paragraph IV certification asserting that the relevant Orange Book patent was invalid, unenforceable, or would not be infringed by Lupin’s proposed generic product.[1] A Paragraph IV certification creates a statutory notice obligation. Once the brand company receives notice, it may file an infringement action within 45 days.

A timely suit invokes the Hatch-Waxman automatic stay. FDA approval of the ANDA is generally stayed for up to 30 months unless the court shortens or extends the period, enters a judgment, or the parties resolve the matter through a settlement.

Exeltis’ complaint alleged that Lupin’s proposed drospirenone product would infringe the asserted patent under 35 U.S.C. § 271(e)(2). That provision treats the submission of an ANDA containing the relevant certification as an artificial act of infringement for purposes of resolving patent rights before generic marketing.

What claims did Exeltis assert against Lupin?

The central claim was patent infringement based on Lupin’s proposed generic composition. The litigation therefore focused on the scope and validity of the composition claims in U.S. Patent No. 10,292,918.

The main technical issues in a drospirenone formulation case of this type typically include:

• The amount and form of drospirenone in the tablet.
• The composition of the excipient matrix.
• Dissolution and release characteristics.
• Stability of the active pharmaceutical ingredient.
• Whether Lupin’s ANDA product falls within the asserted claim limitations.
• Anticipation, obviousness, written description, enablement, and indefiniteness defenses.

The public docket did not produce a claim-construction ruling, invalidity judgment, or infringement judgment that would resolve those issues on a precedential basis.[1]

How strong was Exeltis’ patent position?

Exeltis had a commercially meaningful but litigation-unproven patent position.

Strengths of the Exeltis case

First, the asserted patent was listed in the Orange Book. That listing provided the statutory basis for the Paragraph IV action and delayed FDA approval through the Hatch-Waxman framework.

Second, composition claims can create a direct infringement theory against an ANDA product. If the generic’s quantitative and qualitative composition falls within the claim language, the brand company may not need to rely on a separate method-of-use theory.

Third, Slynd had limited direct generic competition at the time of the case. The patent dispute therefore affected the first potential generic entry into a growing progestin-only contraceptive market.

Limitations of the record

The court did not issue a public opinion determining the validity or enforceability of U.S. Patent No. 10,292,918 in this action. There was no reported trial verdict and no public claim-construction opinion that materially narrowed or upheld the asserted claims.

The settlement therefore does not establish that the patent was valid, that Lupin’s product infringed, or that Lupin’s product design was outside the claims. Its commercial effect depends on the agreed launch date and any licensing provisions, which were not fully disclosed in the public case record.

When could Lupin launch a generic version of Slynd?

A settlement ending the litigation does not necessarily mean immediate generic launch. The relevant date depends on the settlement terms, FDA approval status, regulatory exclusivity, manufacturing readiness, and any other Orange Book patents remaining in force.

The principal launch scenarios are:

Scenario	Commercial effect
Early licensed entry	Lupin may launch before patent expiration under agreed conditions
Delayed entry	Lupin remains blocked until a negotiated date or patent expiry
Authorized generic arrangement	Exeltis or an affiliate may supply or authorize a generic product
FDA approval without immediate marketing	Lupin may obtain approval but defer commercial launch
Remaining patent barrier	Other listed patents may continue to delay or complicate entry

The docket’s public resolution does not establish an unrestricted launch right. A dismissal or settlement should not be treated as proof that Lupin entered the market, received a license, or obtained a particular launch date.

What is the Orange Book status of Slynd?

Slynd was listed in the Orange Book with U.S. Patent No. 10,292,918. The Orange Book listing enabled Exeltis to sue after Lupin’s Paragraph IV notice.[2]

Orange Book implications

The listing had four commercial effects:

1. It put Lupin on notice of the patent barrier.
2. It allowed Exeltis to file a statutory infringement action.
3. It triggered the potential 30-month FDA approval stay.
4. It preserved a mechanism for resolving patent validity and infringement before generic approval.

The Orange Book listing did not itself prove that the patent would survive invalidity challenges. It established the patent’s regulatory significance.

Did Exeltis have formulation, method-of-use, or manufacturing protection?

The reported litigation was primarily a composition-patent dispute. The public case materials do not show a merits ruling involving a separate method-of-use patent or a manufacturing-process patent.

Formulation patents

The asserted patent addressed the pharmaceutical composition containing drospirenone. Formulation patents are often commercially important because they can cover the product that an ANDA applicant must manufacture, even when the active ingredient itself is no longer protected by a compound patent.

Method-of-use patents

Slynd’s contraceptive indication could support method-of-use protection, but the public docket for this action does not show a separate method-of-use patent forming the basis of the final adjudication.

Manufacturing and supply barriers

The case did not produce a public ruling establishing a manufacturing-process barrier. Generic entry would still require Lupin to qualify its manufacturing process, demonstrate bioequivalence, satisfy FDA chemistry, manufacturing, and controls requirements, and produce commercial-scale tablets.

What was the litigation timeline?

Date or period	Event
2022	Exeltis filed the Hatch-Waxman complaint in Delaware
2022	Lupin was named in connection with its ANDA and Paragraph IV certification
2022-2023	Pleadings, scheduling, and discovery proceeded
Before merits judgment	The parties resolved the dispute
Following resolution	The action was closed without a public infringement or invalidity ruling

The litigation did not generate a reported decision addressing the patent’s claim scope or the strength of Lupin’s invalidity defenses.

Was there a settlement agreement?

The case was resolved through a settlement or stipulated dismissal rather than a public merits adjudication. The material commercial terms were not fully disclosed in the publicly available docket materials.[1]

Because Hatch-Waxman settlements can include confidential launch dates, licensing rights, supply arrangements, acceleration provisions, and restrictions tied to regulatory approval, the docket termination alone provides limited information about the parties’ economic agreement.

The absence of a public settlement term sheet also prevents a definitive conclusion about whether Lupin received:

• A license to launch before patent expiration.
• A license contingent on another generic entrant.
• A fixed launch date.
• A right to launch after patent expiry only.
• A supply or authorized-generic arrangement.
• A waiver of damages or other litigation claims.

How did Exeltis v. Lupin affect generic entry risk?

The case reduced immediate generic-entry certainty but did not eliminate long-term entry risk.

For Exeltis, the litigation protected the commercial value of Slynd by forcing the principal generic challenger to resolve the patent dispute before FDA approval or launch. For Lupin, the Paragraph IV filing created a pathway to challenge the patent early and potentially secure a launch date materially before expiration.

The principal risks were:

• A successful Lupin invalidity challenge.
• A finding that Lupin’s product did not infringe.
• A settlement permitting early entry.
• Additional generic ANDA filings by other manufacturers.
• FDA approval of competing products after the applicable stay.
• Commercial erosion from authorized or unbranded alternatives.

A composition patent expiring in the early 2030s could protect Slynd for several years, but the practical exclusivity period depends on the number of surviving Orange Book patents and the outcome of other ANDA challenges.

How does this case compare with biologic patent litigation?

This was a small-molecule Hatch-Waxman case, not a biologic BPCIA dispute.

Issue	Exeltis v. Lupin	Biologic patent litigation
Regulatory pathway	ANDA	BLA and biosimilar application
Product type	Drospirenone tablet	Biologic
Main challenger	Generic applicant	Biosimilar applicant
Key statute	Hatch-Waxman Act	Biologics Price Competition and Innovation Act
Patent listing system	Orange Book	No direct Orange Book equivalent for biologics
Typical dispute	Composition, formulation, method of use	Manufacturing, formulation, antibody or biologic claims

Biosimilar risk was not directly implicated. Lupin’s proposed product was a generic oral contraceptive, not a biosimilar.

What was the revenue exposure for Exeltis?

The case involved a branded contraceptive product rather than a high-revenue biologic or specialty drug. Public materials for the litigation do not establish a definitive product-revenue figure attributable solely to Slynd or the disputed patent.

The financial exposure nonetheless included:

• Loss of price protection following generic entry.
• Reduced prescription volume.
• Lower net sales after generic substitution.
• Pressure on payer and wholesaler pricing.
• Erosion of the value of Exeltis’ U.S. contraceptive portfolio.

The magnitude of exposure depended on Slynd’s prescription growth, payer coverage, the number of generic entrants, the timing of Lupin’s launch, and whether Exeltis maintained an authorized-generic strategy.

Key Takeaways

• Exeltis sued Lupin in Delaware over Lupin’s Paragraph IV challenge to Slynd, a drospirenone 4-mg oral contraceptive.
• The principal patent at issue was U.S. Patent No. 10,292,918.
• The case was a Hatch-Waxman composition-patent dispute.
• The litigation ended without a public merits ruling on infringement, validity, or enforceability.
• The public docket does not establish Lupin’s precise launch date or the full economic terms of the resolution.
• The patent’s expected term extended into the early 2030s, subject to the applicable statutory expiration calculation.
• The dispute created a meaningful but unresolved barrier to generic Slynd entry.
• The case did not involve biosimilar litigation or a BPCIA patent exchange.

FAQs About Exeltis USA v. Lupin

What is Slynd’s active ingredient?

Slynd contains drospirenone, a synthetic progestin, at a 4-mg dose per tablet.

Was Lupin authorized to launch generic Slynd immediately after the case ended?

The public termination of the case does not establish immediate launch authorization. The operative settlement terms were not fully disclosed.

Did the court invalidate Exeltis’ Slynd patent?

No public merits decision in this action invalidated U.S. Patent No. 10,292,918.

Is U.S. Patent No. 10,292,918 a compound patent?

It is directed to pharmaceutical compositions comprising drospirenone rather than broadly claiming drospirenone as a chemical compound.

Does the case block all generic versions of Slynd?

No. The case concerned Lupin’s ANDA and the asserted patent rights against Lupin. Other applicants, other patents, and later regulatory developments can affect generic entry independently.

References

1. Exeltis USA, Inc. v. Lupin Ltd., No. 1:22-cv-00434-RGA-MPT, U.S. District Court for the District of Delaware, docket materials (2022-2024).

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/structs/index.cfm

3. U.S. Patent No. 10,292,918. (2020). Pharmaceutical compositions comprising drospirenone. U.S. Patent and Trademark Office.